Close

Mustang Bio (MBIO) and City of Hope Reports First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) May 18, 2021 08:03AM
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors May 18, 2021 08:00AM
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors May 18, 2021 08:00AM
Mustang Bio (MBIO) and City of Hope Begin Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors Dec 21, 2020 08:12AM
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors Dec 21, 2020 08:00AM


Dec 21, 2020 08:00AM Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Oct 9, 2019 12:00PM City of Hope Is Enrolling Patients in First of Its Kind Clinical Trial for Brain Tumor Patients
Sep 3, 2019 08:00AM Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution
Nov 28, 2018 08:00AM Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
Nov 28, 2018 08:00AM Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
Oct 30, 2018 08:00AM City of Hope Opens First-of-Its-Kind CAR T Clinical Trial for Patients With HER2-positive Breast Cancer That Has Spread to the Brain